Urotensin receptors as a new target for CLP induced septic lung injury in mice

ArticleAçık Erişim

Özet

Sepsis is a life-threatening organ dysfunction condition response resulting in acute lung injury. Urotensin II (UII), an endogenous vasoactive peptide, is widely distributed in pulmonary, cardiovascular, central nervous, renal and metabolic systems, and especially in inflammatory regions. This study aimed to investigate whether urotensin II (UII) and UII receptor (UTR) antagonists play a role in the inflammatory response to sepsis-induced lung damage and they are possible therapeutic targets. In the study, 78 male Balb-c mice were used. A cecal ligation and puncture (CLP)-induced polymicrobial sepsis model was applied, and the effects of human urotensin II (agonist) and urantide and palosuran (antagonists) were investigated on lung tissues. Glutathione and malondialdehyde levels and SOD activity of lung tissues were investigated in addition to TNF-α, IL-1β, IL-6, NF-κB, and UTR mRNA levels. Also, lung sections were histopathologically evaluated. Urantide and palosuran, UII receptor antagonists, decreased proinflammatory cytokines such as TNF-α, IL-1β, IL-6, NF-κB, and also decreased oxidative stress parameters in lung tissue, which are markers of damage. UTR mRNA expression was increased in septic lungs, and both antagonists significantly decreased the elevated receptor level. Also, histopathological examination showed beneficial effects of both agonists on lung tissue. The results of this study help to understand the inflammatory and therapeutic contribution of the UII/UTR system on sepsis-induced lung damage. We can suggest that UTR receptor antagonists may be evaluated as a potential drug which reduces sepsis-induced lung damage in the future. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13755Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s00210-018-1571-8Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorCadirci, Elif
dc.contributor.authorUgan, Rustem Anil
dc.contributor.authorDincer, Busra
dc.contributor.authorGundogdu, Betul
dc.contributor.authorCinar, Irfan
dc.contributor.authorAkpinar, Erol
dc.contributor.authorHalici, Zekai
dc.date.accessioned2026-10-18T20:28:34.583492710Z
dc.date.available2026-10-18T20:28:34.583492710Z
dc.date.issued2019
dc.description.abstractSepsis is a life-threatening organ dysfunction condition response resulting in acute lung injury. Urotensin II (UII), an endogenous vasoactive peptide, is widely distributed in pulmonary, cardiovascular, central nervous, renal and metabolic systems, and especially in inflammatory regions. This study aimed to investigate whether urotensin II (UII) and UII receptor (UTR) antagonists play a role in the inflammatory response to sepsis-induced lung damage and they are possible therapeutic targets. In the study, 78 male Balb-c mice were used. A cecal ligation and puncture (CLP)-induced polymicrobial sepsis model was applied, and the effects of human urotensin II (agonist) and urantide and palosuran (antagonists) were investigated on lung tissues. Glutathione and malondialdehyde levels and SOD activity of lung tissues were investigated in addition to TNF-α, IL-1β, IL-6, NF-κB, and UTR mRNA levels. Also, lung sections were histopathologically evaluated. Urantide and palosuran, UII receptor antagonists, decreased proinflammatory cytokines such as TNF-α, IL-1β, IL-6, NF-κB, and also decreased oxidative stress parameters in lung tissue, which are markers of damage. UTR mRNA expression was increased in septic lungs, and both antagonists significantly decreased the elevated receptor level. Also, histopathological examination showed beneficial effects of both agonists on lung tissue. The results of this study help to understand the inflammatory and therapeutic contribution of the UII/UTR system on sepsis-induced lung damage. We can suggest that UTR receptor antagonists may be evaluated as a potential drug which reduces sepsis-induced lung damage in the future. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
dc.description.sponsorshipFunding information This study was supported by Turkish Academy of Sciences (TUBA)\u2014The Young Scientist Award Program (GEBIP) with project number BEC/TUBAGEBIP-20135.^
dc.identifier.doi10.1007/s00210-018-1571-8
dc.identifier.eissn1432-1912
dc.identifier.endpage145
dc.identifier.issn0028-1298
dc.identifier.issue2
dc.identifier.pmcid3232386
dc.identifier.pmid30353214
dc.identifier.scopus2-s2.0-85055719689
dc.identifier.startpage135
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13755
dc.identifier.volume392
dc.identifier.wosWOS:000457408700002
dc.language.isoen
dc.publisherSpringer Verlag
dc.relation.ispartofNaunyn-Schmiedeberg's Archives of Pharmacology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectLung damage
dc.subjectPalosuran
dc.subjectSepsis
dc.subjectUrantide
dc.subjectUrotensin
dc.subjectUrotensin receptor
dc.subjectAcute Lung Injury
dc.subjectAnimals
dc.subjectCecum
dc.subjectCytokines
dc.subjectGene Expression
dc.subjectGlutathione
dc.subjectLigation
dc.subjectLung
dc.subjectMale
dc.subjectMalondialdehyde
dc.subjectMice, Inbred BALB C
dc.subjectNF-kappa B
dc.subjectPeptide Fragments
dc.subjectQuinolines
dc.subjectReceptors, G-Protein-Coupled
dc.subjectSuperoxide Dismutase
dc.subjectUrea
dc.subjectUrotensins
dc.subjectimmunoglobulin enhancer binding protein
dc.subjectinterleukin 1beta
dc.subjectinterleukin 6
dc.subjectmalonaldehyde
dc.subjecttumor necrosis factor
dc.subject1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea
dc.titleUrotensin receptors as a new target for CLP induced septic lung injury in mice
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus39
rdl.citation.wos39
rdl.departmentDepartment of Pharmacology, Faculty of Pharmacy, Erzincan Binali Yildirim University, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)